On July 25, 2015, the eighth subject was treated in our ongoing study of MDMA-assisted therapy for social anxietyin 12 adults on the autism spectrum. As of July 30, five subjects have completed their six-month follow-up visit. Sponsored by MAPS, this is a collaborative study between MAPS and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, with blood plasma biomarker analysis being conducted by researchers at Stanford University. "The interesting thing about MDMA and similar drugs…is that they do have multi-targeted approaches," says Stanford University School of Medicine researcher Dean Carson, Ph.D. "We’re talking about the effects of serotonin, dopamine, oxytocin, cortisol, vasopressin…It’s really a systems-level approach that I think is very important in the treatment of psychiatric disorders." Watch the video
